Pasar al contenido principal

MECANISMOS MOLECULARES IMPLICADOS EN LAS DIFERENCIAS DE PATOGENICIDAD EN COMBINACIONES FAVORABLES Y NO FAVORABLES DE M. TUBERCULOSIS Y EL HOSPEDADOR

PID2021-123443OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2021
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSITAT DE VALÈNCIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero-Abadía, Paula
  • Ruiz-Rodríguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard
  • Chiner-Oms, Álvaro
  • Torres-Puente, Manuela
  • Comas, Iñaki
  • Julián, Esther
  • Coscollá, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential., This research was funded by the Spanish Ministry of Science, Innovation, and Universities (MICIN) and co-funded by the FEDER Funds (RTI2018-098777-B-I00, RTI2018-094399-A-I00, PID2021-125801OB-I00, PID2021-122331OB-I00, and PID2021-123443OB-I00), the AGAUR-Generalitat of Catalunya (2017SGR229 and 2017SGR-1079), Ramón y Cajal fellowship (RYC-2015-18213 MICIN), FPI fellowship (PRE-2019-088141 MICIN), Generalitat Valenciana (SEJI/2019/011), MycoNET (RED2018-102677-T), and the European Commission—NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Program (PTI+ Salud Global)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

VIPERA: Viral Intra-Patient Evolution Reporting and Analysis

  • Álvarez-Herrera, Miguel
  • Sevilla, Jordi
  • Ruiz-Rodríguez, Paula
  • Vergara, Andrea
  • Vila, Jordi
  • Cano-Jiménez, Pablo
  • González-Candelas, Fernando
  • Comas, Iñaki
  • Coscollá, Mireia
Viral mutations within patients nurture the adaptive potential of SARS-CoV-2 during chronic infections, which are a potential source of variants of concern. However, there is no integrated framework for the evolutionary analysis of intra-patient SARS-CoV-2 serial samples. Herein we describe VIPERA (Viral Intra-Patient Evolution Reporting and Analysis), a new software that integrates the evaluation of the intra-patient ancestry of SARS-CoV-2 sequences with the analysis of evolutionary trajectories of serial sequences from the same viral infection. It has been validated using positive and negative control datasets and successfully applied to a novel case, contributing to easy and automatic analysis of intra-patient SARS-CoV-2 sequences., This work was funded by the Spanish Ministry of Science (CNS2022-135116) and the European Commission – NextGenerationEU (Regulation EU 2020/2094), through the Global Health Platform (PTI+ Salud Global) of the Spanish National Research Council (CSIC). MAH and PRR are supported by the PTI+ Salud Global. JS is supported by the CSIC’s JAE intro programme. FGC was funded by project PID2021-127010OB-I00 from the Spanish Ministry of Science and CIPROM2021-053 from the Generalitat Valenciana. IC is funded by the European Research Council (101001038-TB640 RECONNECT) and the Spanish Ministry of Economy, Industry and Competitiveness (PID2019- 104477RB-I00). MC is funded by the Spanish Ministry of Science (PID2021-123443OB-I00)., No
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

VIPERA: Viral Intra-Patient Evolution Reporting and Analysis

  • Álvarez-Herrera, Miguel
  • Sevilla, Jordi
  • Ruiz-Rodríguez, Paula
  • Vergara, Andrea
  • Vila, Jordi
  • Cano-Jiménez, Pablo
  • González-Candelas, Fernando
  • Comas, Iñaki
  • Coscollá, Mireia
15 páginas, 9 figuras, Viral mutations within patients nurture the adaptive potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during chronic infections, which are a potential source of variants of concern. However, there is no integrated framework for the evolutionary analysis of intra-patient SARS-CoV-2 serial samples. Herein, we describe Viral Intra-Patient Evolution Reporting and Analysis (VIPERA), a new software that integrates the evaluation of the intra-patient ancestry of SARS-CoV-2 sequences with the analysis of evolutionary trajectories of serial sequences from the same viral infection. We have validated it using positive and negative control datasets and have successfully applied it to a new case, which revealed population dynamics and evidence of adaptive evolution. VIPERA is available under a free software license at https://github.com/PathoGenOmics-Lab/VIPERA., This work is a part of project CNS2022-135116 funded by MCIN/AEI/10.13039/501100011033, by the European Union Next GenerationEU/PRTR, and grant PID2021-123443OB-I00 funded by MICIN/AEI/10.13039/501100011033 and ERDF A way of making Europe. M.A.H. and P.R.R. are supported by the PTI+ Salud Global European Commission – NextGenerationEU (Regulation EU 2020/2094). J.S. is supported by the CSIC’s JAE intro program. F.G.C. was funded by project PID2021-127010OB-I00 from the Spanish Ministry of Science and CIPROM2021-053 from the Generalitat Valenciana. I.C. is funded by the European Research Council (101001038-TB-RECONNECT) and the Spanish Ministry of Economy, Industry and Competitiveness (PID2019-104477RB-I00)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Phylogenomic insights into brucellaceae: The Pseudochrobactrum algeriensis case

  • Loperena-Barber, Maite
  • Elizalde-Bielsa, Aitor
  • Salvador-Bescós, Miriam
  • Ruiz-Rodríguez, Paula
  • Pellegrini, Joaquin Miguel
  • Renau-Mínguez, Chantal
  • Lancaster, Rebecca
  • Zúñiga-Ripa, Amaia
  • Iriarte, Maite
  • Bengoechea, Jose A.
  • Coscollá, Mireia
  • Gorvel, Jean-Pierre
  • Moriyón, Ignacio
  • Conde-Álvarez, Raquel
The genus Pseudochrobactrum encompasses free-living bacteria phylogenetically close to Ochrobactrum opportunistic pathogens and to Brucella, facultative intracellular parasites causing brucellosis, a worldwide-extended and grave zoonosis. Recently, Pseudochrobactrum strains were isolated from Brucella natural hosts on Brucella selective media, potentially causing diagnostic confusions. Strikingly, P. algeriensis was isolated from cattle lymph nodes, organs that are inimical to bacteria. Here, we analyse P. algeriensis potential virulence factors in comparison with Ochrobactrum and Brucella. Consistent with genomic analyses, Western-Blot analyses confirmed that P. algeriensis lacks the ability to synthesize the N-formylperosamine O-polysaccharide characteristic of the lipopolysaccharide (LPS) of smooth Brucella core species. However, unlike other Pseudochrobactrum but similar to some early diverging brucellae, P. algeriensis carries genes potentially synthetizing a rhamnose-based O-polysaccharide LPS. Lipid A analysis by MALDI-TOF demonstrated that P. algeriensis LPS bears a lipid A with a reduced pathogen-associated molecular pattern, a trait shared with Ochrobactrum and Brucella that is essential to generate a highly stable outer membrane and to delay immune activation. Also, although not able to multiply intracellularly in macrophages, the analysis of P. algeriensis cell lipid envelope revealed the presence of large amounts of cationic aminolipids, which may account for the extremely high resistance of P. algeriensis to bactericidal peptides and could favor colonization of mucosae and transient survival in Brucella hosts. However, two traits critical in Brucella pathogenicity are either significantly different (T4SS [VirB]) or absent (erythritol catabolic pathway) in P. algeriensis. This work shows that, while diverging in other characteristics, lipidic envelope features relevant in Brucella pathogenicity are conserved in Brucellaceae. The constant presence of these features strongly suggests that reinforcement of the envelope integrity as an adaptive advantage in soil was maintained in Brucella because of the similarity of some environmental challenges, such as the action of cationic peptide antibiotics and host defense peptides. This information adds knowledge about the evolution of Brucellaceae, and also underlines the taxonomical differences of the three genera compared., Research at the University of Navarra was supported by grants PID2019-107601RA-C32 (MCIN/AEI/10.13039/501100011033) and REPRODIVAC project under Grant Agreement No. 10106081 through the HORIZON-CL6-2021-FARM2FORK-01-06 Call. M.L.-B. was recipient of the PhD Fellowships Formación de Profesorado Universitario (FPU) funded by Ministerio de Ciencia, Innovación y Universidad (Spanish Government) and Ayuda predoctoral from Gobierno de Navarra. A.E.-B. was recipient of the PhD Fellowship funded by ISTUN (Institute of Tropical Health, University of Navarra). Research at Institute for Integrative Systems Biology, Universidad de Valencia-CSIC was supported by project PID2021-123443OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by FEDER, UE., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Differences in virulence of M. tuberculosis ecotypes based on host specificity

  • Caballer-Gual, Marta
  • Santamaria, Guillem
  • Gomis-Olcina, Carlos
  • Renau-Mínguez, Chantal
  • Espert, Antonio
  • Ruiz-Rodríguez, Paula
  • Coscollá, Mireia
Trabajo presentado al 60 aniversario de la Sociedad Española de Bioquímica y Biología Molecular (SEBBM), celebrado en Valencia (España) el día 2 de junio de 2023., This work is part of the R+D+i project Molecular mechanisms associated with differences in pathogenicity in favored and unfavored combinations of M. tuberculosis and host (mol-TBhost) with reference PID2021-123443OB-I00 and financed by MCIN/AEI/ 10.13039/501100011033/ “FEDER Una manera de hacer Europa” or by the “European Union NextGenerationEU/PRTR”., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Host specific in vitro virulence patterns of different Mycobacterium tuberculosis ecotypes

  • Ruiz-Rodríguez, Paula
  • Caballer-Gual, Marta
  • Hiza, Hellen
  • Galvis-Jimenez, J.
  • Coscollá, Mireia
Trabajo presentado a la reunión de MycoNET, celebrada en Leganes, Madrid el día 27 de noviembre de 2023., This work is part of the R+D+i project Molecular mechanisms associated with differences in pathogenicity in favored and unfavored combinations of M tuberculosis and host (mol TBhost) with reference PID2021-123443-OB I00 and financed by MCIN/AEI/ 10 13039 501100011033 //“FEDER Una manera de hacer Europa” or by the “European Union NextGenerationEU/PRTR”., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic analysis of Mycobacterium brumae sustains its nonpathogenic and immunogenic phenotype

  • Renau-Mínguez, Chantal
  • Herrero Abadía, Paula|||0000-0001-9747-1818
  • Ruiz-Rodriguez, Paula
  • Sentandreu, Vicente
  • Torrents, Eduard|||0000-0002-3010-1609
  • Chiner-Oms, Álvaro|||0000-0002-0463-0101
  • Torres-Puente, Manuela|||0000-0002-8352-180X
  • Comas, I.|||0000-0001-5504-9408
  • Julián, Esther|||0000-0002-6558-3978
  • Coscolla, Mireia
Mycobacterium brumae is a rapid-growing, non-pathogenic Mycobacterium species, originally isolated from environmental and human samples in Barcelona, Spain. Mycobacterium brumae is not pathogenic and it's in vitro phenotype and immunogenic properties have been well characterized. However, the knowledge of its underlying genetic composition is still incomplete. In this study, we first describe the 4 Mb genome of the M. brumae type strain ATCC 51384 T assembling PacBio reads, and second, we assess the low intraspecies variability by comparing the type strain with Illumina reads from three additional strains. Mycobacterium brumae genome is composed of a circular chromosome with a high GC content of 69.2% and containing 3,791 CDSs, 97 pseudogenes, one prophage and no CRISPR loci. Mycobacterium brumae has shown no pathogenic potential in in vivo experiments, and our genomic analysis confirms its phylogenetic position with other non-pathogenic and rapid growing mycobacteria. Accordingly, we determined the absence of virulence-related genes, such as ESX-1 locus and most PE/PPE genes, among others. Although the immunogenic potential of M. brumae was proved to be as high as Mycobacterium bovis BCG, the only mycobacteria licensed to treat cancer, the genomic content of M. tuberculosis T cell and B cell antigens in M. brumae genome is considerably lower than those antigens present in M. bovis BCG genome. Overall, this work provides relevant genomic data on one of the species of the mycobacterial genus with high therapeutic potential.